MRP1 displayed a higher degree of drug substrate recognition than BCRP, leading to a 2.5-8.8-fold increase in the IC50 values in the MRP1-overexpressing ovarian cancer cell line 2008/MRP1 [50]; co-treatment with the potent MRP1 transport inhibitor MK571 fully restored cellular sensitivity to these drugs, indicating that this drug resistance was solely mediated by MRP1. This evidence concerns the gene ABCC1 and ovarian cancer.